Background: Controversy remains regarding the impact of anti-TNFα agents on postoperative outcomes in Crohn’s disease. Methods: Patients (≥ 18 years) with Crohn’s disease (ICD-9, 555.0–555.2, 555.9) undergoing ileocolectomy between 2005 and 2013 were identified using the Truven MarketScan® database and stratified by receipt of anti-TNFα therapy. Multivariable logistic regression was performed to evaluate anti-TNFα use on emergency department (ED) visits, postoperative complications, and readmissions at 30 days, adjusting for potential confounders. Relationships between timing of anti-TNFα administration and outcomes were examined. Results: The sample contained 2364 patients with Crohn’s disease undergoing ileocolectomy, with 28.5% (n = 674) who received biologic therapy. Median duration between anti-TNFα therapy and surgery was 33 days. Postoperative ED visits and readmission rates did not significantly differ among those receiving biologics and those that did not. Overall 30-day complication rates were higher among those receiving biologic therapy, namely related to wound and infectious complications. In multivariable analysis, anti-TNFα inhibitors were associated with increased odds of postoperative complications at 30 days (aggregate complications [OR 1.6], infectious complications [OR 1.5]). There was no significant association between timing of anti-TNFα administration and occurrence of postoperative outcomes. Conclusion: Anti-TNFα therapy is independently associated with increased postoperative infectious complications following ileocolectomy in Crohn’s disease. However, in patients receiving anti-TNFα therapy within 90 days of operative intervention, further delaying surgery may not attenuate risk of postoperative complications.

Original languageEnglish (US)
Pages (from-to)467-474
Number of pages8
JournalJournal of Gastrointestinal Surgery
Issue number2
StatePublished - Feb 2021

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology


Dive into the research topics of 'The Impact of Preoperative Anti-TNFα Therapy on Postoperative Outcomes Following Ileocolectomy in Crohn’s Disease'. Together they form a unique fingerprint.

Cite this